Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

NYSE:DNA   3:59:59 PM EDT
5.80
-0.34 (-5.54%)
: $5.69 -0.11 (-1.90%)
Products

Selecta Biosciences And Ginkgo Bioworks Announce New Collaboration To Develop Next-Generation Gene Therapy Capsids

Published: 01/10/2022 13:01 GMT
Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A (DNA) - Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-generation Gene Therapy Capsids.
Selecta Biosciences - Ginkgo is Eligible to Earn Upfront Research and Development Fees, Milestone Payments, Including Certain Payments in Form of Co's Common Stock.
Selecta Biosciences - Ginkgo is Eligible to Earn Milestone Payments of Up to $200 Million in Cash for Each of Specified Number of Products.
Selecta Biosciences Inc - Milestone Payments for Ginkgo Have Potential to Total, in Aggregate, Up to $1.1 Billion.
Selecta Biosciences Inc - Ginkgo is Also Entitled to Potential Further Downstream Value in Form of Royalties on Sales.
Selecta Biosciences Inc - Ginkgo Plans to Design and Engineer Capsids and Co to Conduct All Pre-clinical and Clinical Studies Thereafter.